How life-sciences teams use one System of Proof, from discovery to post-market.

One platform, adopted one workflow at a time

One platform, adopted one workflow at a time

Life-sciences companies adopt software one department at a time. TFives is built for that: one System of Proof underneath, and workflows that plug into it as you grow.

Life-sciences companies adopt software one department at a time. TFives is built for that: one System of Proof underneath, and workflows that plug into it as you grow.

System of Proof — built once

Identity, rules, evidence and audit trail: who acted, which rule applied, what evidence was used, and when.

Workflows — added as you grow

Quality, regulatory, safety, medical information and promotional review, all writing to the same record.

Why it matters: Inspectors follow a process across departments: a deviation into a CAPA, and the CAPA into a submission. On one core, that thread is already connected.

1

Start with one workflow, where compliance pressure is highest.

2

Add the next. It inherits the same identity, rules and evidence.

3

Extend across the lifecycle, from discovery to post-market.

From day one

AI drafts; qualified people approve.

High-risk actions outside approved use are held for a person to decide.

Your data stays in your environment.

Your QMS, RIM and content systems stay in place.

As you grow

Each new workflow deploys faster.

Evidence is reused, not rebuilt.

Changes trigger review and change control.

Independent proof for any AI, whoever built it.

TFives is not a replacement for your systems of record, an autonomous decision-maker, or a filing service.

From discovery to post-market

From discovery to post-market

Each workflow on the map is a case study below.

Map of the journey from lab to market, with numbered stories
Pick the right ideas: story 1

Planning · Story 1

Prioritize AI use cases before funding

Target

Up to 60%

less time to a go / no-go decision

Targets are indicative pilot goals, not guaranteed results.

Problem: AI ideas were funded first and assessed for compliance at go-live.

Approach: Each use case was scored for fit, integrity, validation, economics and scale before funding.

Outcome: Ready use cases move ahead; the rest are deferred with clear gaps.

Connects to: Safety case intake (Story 2)

Keep patients safe: story 2

Development → Post-market · Story 2

Safety case intake, from trial to market

Target

50–60%

less time on safety case intake

Problem: Safety reports, clocks and decisions were spread across inboxes.

Approach: One case record from clinical trial through post-market. Qualified reviewers decide; AI assists.

Outcome: The same evidence before and after launch.

Connects to: Medical information (Story 7)

Keep tests up to date: story 3

Development · Story 3

Keep diagnostic assays submission-ready

Target

Up to 75%

less time to confirm what’s current

Problem: Teams were unsure which assay version was in force and what evidence was missing.

Approach: One trail of versions, evidence and open checklist items, with controlled partner access.

Outcome: Clear answers without rebuilding the history from email.

Connects to: Regulatory & MLR approvals (Story 4)

One trail for approvals: story 4

Development · Story 4

One approval trail for regulatory and MLR

Target

50–60%

shorter review cycles

Problem: Answering “who approved this?” took days.

Approach: Every draft cites its sources, and each step needs a named approver.

Outcome: Reviews focus on the decision, not on reconstructing history.

Connects to: AI-assisted CAPA (Story 5)

Fix problems properly: story 5

Manufacturing · Story 5

AI-assisted CAPA, with proof

Target

Up to 60%

less time documenting CAPA steps

Problem: AI could help with investigations, but validation couldn’t accept unreviewed AI output.

Approach: AI assists only after it is allowed. Held steps are recorded too.

Outcome: Faster investigations, with evidence for every step.

Connects to: Regulatory & MLR approvals (Story 4)

Ads match approvals: story 6

Launch · Story 6

Keep live promotions matched to approvals

Target

Up to 75%

less time to catch live-content drift

Problem: Approved content drifted once it went live.

Approach: Claims checked before sign-off and monitored after launch.

Outcome: Drift is caught early and ranked by severity.

Connects to: Regulatory & MLR approvals (Story 4)

Answer doctors safely: story 7

Post-market · Story 7

Label-grounded medical information

Target

50–70%

faster routine answers

Problem: Rising HCP questions, some of which were really safety reports.

Approach: Answers use only approved sources. Possible adverse events are flagged and escalated for pharmacovigilance intake.

Outcome: Faster routine answers, with possible safety reports escalated, not answered.

Connects to: Safety case intake (Story 2)

Under every workflow: one System of Proof.

Under every workflow: one System of Proof.

Every stage · Story 8

Allowed to Act™: prove every AI action was permitted

Target

Up to 75%

less time preparing audit evidence

Problem: AI pilots stalled because no one could prove what the AI did.

Approach: Three checks before every high-risk action: who is acting, whether it is allowed, and whether it is the approved AI.

Outcome: Every governed action can be replayed for an inspector.

Connects to: Every workflow on this page.

Prove the AI was allowed: story 8

Start with one workflow.

Start with one workflow.

Choose the area with the greatest compliance pressure. Every workflow after it builds on the same record.

Targets are indicative, based on typical industry baselines and pilot goals. They are not guaranteed results. Customer names withheld. Screens show demo data.